Drug Approval | September 12, 2021
US FDA grants Soligenix Orphan Drug Designation for the treatment of T-cell lymphoma
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
Over 70 per cent of the world’s population have no access to MRI scanners and the situation is not that encouraging in India where there are only 0.4 MRI scanners per thousand people
HTL will build, validate and operate a botulinum manufacturing facility in the US
Nipah virus (NiV) is an emerging zoonotic disease that causes severe disease in humans. Signs and symptoms range from asymptomatic to acute respiratory infection and fatal encephalitis
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
Labetalol hydrochloride injection USP is indicated for the control of blood pressure in severe hypertension.
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
Subscribe To Our Newsletter & Stay Updated
